Literature DB >> 1754746

The costs of treating hypertension in Sweden. An empirical investigation in primary health care.

M Johannesson1, L Borgquist, B Jönsson.   

Abstract

The treatment costs of hypertension in Sweden were calculated both at the individual and at the national level after an empirical investigation in primary health care. The average drug cost per patient and year was calculated as c. SEK 1220, the annual consultation cost as c. SEK 620, and the annual travel and time cost as c. SEK 230. About 500,000 people are treated pharmacologically for hypertension in Sweden, and about 25,000 non-pharmacologically. The total annual treatment cost for these patients was calculated as c. SEK 1100 million. The drug cost accounts for c. SEK 650 million, the consultation cost for c. SEK 330 million, and the travel and time cost for c. SEK 120 million. The drug reimbursement scheme pays almost half these costs, while the county councils and the patients pay approximately a quarter each.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1754746     DOI: 10.3109/02813439109018511

Source DB:  PubMed          Journal:  Scand J Prim Health Care        ISSN: 0281-3432            Impact factor:   2.581


  12 in total

1.  Drug expenditure and new drug introductions: the Swedish experience.

Authors:  U G Gerdtham; M Johannesson; B Jönsson
Journal:  Pharmacoeconomics       Date:  1993-09       Impact factor: 4.981

Review 2.  Selective versus nonselective beta adrenoceptor antagonists in hypertension.

Authors:  L M Van Bortel; A J Ament
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

Review 3.  Enalapril: a review of quality-of-life and pharmacoeconomic aspects of its use in heart failure and mild to moderate hypertension.

Authors:  M I Wilde; H M Bryson; K L Goa
Journal:  Pharmacoeconomics       Date:  1994-08       Impact factor: 4.981

4.  A review of cost-effectiveness analyses of hypertension treatment.

Authors:  M Johannesson; B Jönsson
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

5.  The cost effectiveness of hypertension treatment in Sweden.

Authors:  M Johannesson
Journal:  Pharmacoeconomics       Date:  1995-03       Impact factor: 4.981

Review 6.  Defining the patient group for cost-effective withdrawal of antihypertensive therapy.

Authors:  L R Krakoff; S Wassertheil-Smoller
Journal:  Pharmacoeconomics       Date:  1995-03       Impact factor: 4.981

7.  The cost of angina pectoris in Sweden.

Authors:  F Andersson; B Kartman
Journal:  Pharmacoeconomics       Date:  1995-09       Impact factor: 4.981

Review 8.  Pharmacoeconomic considerations in the management of hypertension.

Authors:  H Pardell; R Tresserras; P Armario; R Hernández del Rey
Journal:  Drugs       Date:  2000       Impact factor: 9.546

9.  Cost-effectiveness of fracture prevention in established osteoporosis.

Authors:  B Jönsson; C Christiansen; O Johnell; J Hedbrandt
Journal:  Osteoporos Int       Date:  1995-03       Impact factor: 4.507

10.  Physical activity on prescription (PAP): costs and consequences of a randomized, controlled trial in primary healthcare.

Authors:  Asa Romé; Ulf Persson; Charlotte Ekdahl; Gunvor Gard
Journal:  Scand J Prim Health Care       Date:  2009       Impact factor: 2.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.